PE20050207A1 - Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas - Google Patents

Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas

Info

Publication number
PE20050207A1
PE20050207A1 PE2004000541A PE2004000541A PE20050207A1 PE 20050207 A1 PE20050207 A1 PE 20050207A1 PE 2004000541 A PE2004000541 A PE 2004000541A PE 2004000541 A PE2004000541 A PE 2004000541A PE 20050207 A1 PE20050207 A1 PE 20050207A1
Authority
PE
Peru
Prior art keywords
alkylene
linear
referring
composition including
progesterone receptor
Prior art date
Application number
PE2004000541A
Other languages
English (en)
Inventor
Ulrike Furhrmann
Jens Hoffmann
Martin Schneider
Gerhard Siemeister
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20050207A1 publication Critical patent/PE20050207A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE (A) AL ANTAGONISTA DE RECEPTORES DE PROGESTERONA 11b-(4-ACETILFENIL)-17b-HIDROXI-17a-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA Y (B) AL MENOS UN ANTIESTROGENO PURO DE FORMULA I DONDE Hal ES F, CL; R3 ES H, ALQUILO C1-C4, ALCANOILO C1-C4, ETER CICLICO C3-C7 CON UN O; R17' ES H, ALQUILO C1-C4, ALCANOILO C1-C4; R17" ES ALQUIL C1-C4, ALQUINILO C1-C4, ENTRE OTROS; SK ES U-V-W-X-Y-Z-E; U ES ALQUILENO C1-C13, ALQUINILENO LINEAL O RAMIFICADO; V ES CH2, C(O); W ES NH, ANILLO AZOLIDINELO, ANILLO AZOLIDINILENO-N-OXIDO, ENTRE OTROS; X ES ALQUILENO C1-12, ALQUINILENO LINEAL O RAMIFICADO; Y ES ENLACE DIRECTO, ALQUILENO, O-ALQUILENO, ENTRE OTROS; Z ES ENLACE DIRECTO ALQUILENO C1-C9, ALQUENILO LINEAL O RAMIFICADO, ENTRE OTROS; E ES CF3, ARILO, ENTRE OTROS. (A) Y (B) ESTAN EN RELACION DE 1:100, 100:1, 1:4 Y DE 4:1. SE ADMINISTRAN A DIFERENTES CONCENTRACIONES DE DOSIS UNITARIA Y SON UTILES PARA TRATAR ENFERMEDADES DEPENDIENTES DE HORMONAS COMO CANCER DE MAMA
PE2004000541A 2003-05-28 2004-05-28 Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas PE20050207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
PE20050207A1 true PE20050207A1 (es) 2005-04-28

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000541A PE20050207A1 (es) 2003-05-28 2004-05-28 Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas

Country Status (18)

Country Link
US (3) US20040242551A1 (es)
EP (2) EP1834644A3 (es)
JP (1) JP2006528226A (es)
KR (1) KR20060005412A (es)
CN (1) CN1893955A (es)
AR (1) AR044450A1 (es)
AU (1) AU2004243500A1 (es)
BR (1) BRPI0410707A (es)
CA (1) CA2524750A1 (es)
CL (1) CL2004001317A1 (es)
EA (1) EA011506B1 (es)
MX (1) MXPA05012841A (es)
NO (1) NO20056153L (es)
PE (1) PE20050207A1 (es)
TW (1) TW200505936A (es)
UY (1) UY28334A1 (es)
WO (1) WO2004105768A1 (es)
ZA (1) ZA200510449B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
WO2004111024A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
EP2983671B1 (en) * 2013-04-11 2018-10-24 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
WO2002032430A1 (en) * 2000-10-18 2002-04-25 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
UA76729C2 (uk) * 2000-10-18 2006-09-15 Шерінг Акцієнгезельшафт ЗАСТОСУВАННЯ АНТИПРОГЕСТИНУ 11<font face="Symbol">b</font>-(4-АЦЕТИЛФЕНІЛ)-17<font face="Symbol">b</font>-ГІДРОКСИ-17<font face="Symbol">a</font>-(1,1,2,2,2-ПЕНТАФТОРЕТИЛ)ЕСТРА-4,9-ДІЄН-3-ОНУ ДЛЯ ЛІКУВАННЯ РАКУ ШЛЯХОМ ІНДУКУВАННЯ АПОПТОЗУ КЛІТИНИ
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
CL2004001317A1 (es) 2005-05-06
EA200501739A1 (ru) 2006-06-30
US20070238714A1 (en) 2007-10-11
AR044450A1 (es) 2005-09-14
US20040242551A1 (en) 2004-12-02
ZA200510449B (en) 2007-04-25
EA011506B1 (ru) 2009-04-28
WO2004105768A8 (en) 2006-04-06
BRPI0410707A (pt) 2006-06-13
CA2524750A1 (en) 2004-12-09
EP1834644A3 (en) 2007-11-07
WO2004105768A1 (en) 2004-12-09
EP1834644A2 (en) 2007-09-19
EP1628669A1 (en) 2006-03-01
US20050014736A1 (en) 2005-01-20
CN1893955A (zh) 2007-01-10
MXPA05012841A (es) 2006-02-13
KR20060005412A (ko) 2006-01-17
JP2006528226A (ja) 2006-12-14
NO20056153L (no) 2006-02-22
UY28334A1 (es) 2004-12-31
TW200505936A (en) 2005-02-16
AU2004243500A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
PE20030727A1 (es) 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
UY27760A1 (es) Nuevos derivados de pirrolidinio.
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
AR058838A1 (es) Metodo para tratar el dano articular
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
UY28873A1 (es) Nuevos compuestos de morfina composiciones y procedimientos de preparación
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
UY28516A1 (es) Derivados de quinazolina
AR115663A1 (es) Compuestos
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
AR052345A1 (es) Composicion para cuidado oral del mal aliento
UY31403A1 (es) &#34;derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos&#34;.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
PE20050207A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas
UY28519A1 (es) Derivados de quinazolina
AR046756A1 (es) Derivados de hidronopol como agonistas de receptores orl-1 humanos.
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed